[18F]MK-6240

3 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Humans3

Outcomes

Noise to dynamic range ratio

downin humans2

2 studies

[18F]MK-6240 decreases noise to dynamic range ratio in humans.
“[ 18 F]MK6240 consistently demonstrated lower NRR, implying better detectability across all regions, cross‐sectionally and longitudinally.”
Humanscross-sectionally across regions
In vivo detectability of tau‐PET tracers in Alzheimer's disease
AAIC 2025 abstract8 Jan 2026
[18F]MK-6240 decreases noise to dynamic range ratio in humans.
“Across the whole cohort, [ 18 F]MK6240 exhibited lower NRR than [ 18 F]FTP in all regions.”
Humanscross-sectionally across the whole cohortbrain
In vivo detectability of tau‐PET tracers in Alzheimer’s disease
AAIC 2025 abstract23 Dec 2025

Associations

tau-PET overlap index

mixedin humans1

1 study

[18F]MK-6240 is associated with tau-PET overlap index in humans.
“OI values within the META‐ROI exhibited a broad distribution between [ 18 F]MK‐6240 and [ 18 F]AV‐1451 tau‐PET, particularly in cognitively unimpaired (CU) and younger individuals”
Humansin serial tau-PET scans
Evaluation discrepancy between [ ¹⁸ F]MK‐6240 and [ ¹⁸ F]AV‐1451 tau‐PET using tau‐PET overlap index
AAIC 2025 abstract11 Jan 2026